[HTML][HTML] Clinical strategies for acquired epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer patients
L Dong, D Lei, H Zhang - Oncotarget, 2017 - ncbi.nlm.nih.gov
Epidermal growth factor receptor (EGFR) mutations (EGFRm+) occur in 10–35% of non-
small-cell lung cancer (NSCLC) cases and confer sensitivity to EGFR tyrosine kinase …
small-cell lung cancer (NSCLC) cases and confer sensitivity to EGFR tyrosine kinase …
[HTML][HTML] Lysine Deprivation Induces AKT-AADAT Signaling and Overcomes EGFR-TKIs Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells
CC Hsu, AYP Yang, JY Chen, HH Tsai, SH Lin, PC Tai… - Cancers, 2021 - mdpi.com
Simple Summary In the Asian population, 50–60% of non-small cell lung cancer (NSCLC)
patients carry the epidermal growth factor receptor (EGFR) mutation. Although treatment with …
patients carry the epidermal growth factor receptor (EGFR) mutation. Although treatment with …
Amplification of EGFR wild-type alleles in non–small cell lung cancer cells confers acquired resistance to mutation-selective EGFR tyrosine kinase inhibitors
S Nukaga, H Yasuda, K Tsuchihara, J Hamamoto… - Cancer research, 2017 - AACR
EGFR-mutated lung cancers account for a significant subgroup of non–small cell lung
cancers overall. Third-generation EGFR tyrosine kinase inhibitors (TKI) are mutation …
cancers overall. Third-generation EGFR tyrosine kinase inhibitors (TKI) are mutation …
Single-cell analyses reveal diverse mechanisms of resistance to EGFR tyrosine kinase inhibitors in lung cancer
Y Kashima, D Shibahara, A Suzuki, K Muto… - Cancer research, 2021 - AACR
Tumor heterogeneity underlies resistance to tyrosine kinase inhibitors (TKI) in lung cancers
harboring EGFR mutations. Previous evidence suggested that subsets of preexisting …
harboring EGFR mutations. Previous evidence suggested that subsets of preexisting …
[HTML][HTML] Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring
D Reita, L Pabst, E Pencreach, E Guérin, L Dano… - Cancers, 2021 - mdpi.com
Simple Summary Non-small cell lung cancer (NSCLC) is the most common cancer in the
world. For common EGFR mutations, treatment is based on different inhibitors. Despite the …
world. For common EGFR mutations, treatment is based on different inhibitors. Despite the …
[HTML][HTML] Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells
K Tabara, R Kanda, K Sonoda, T Kubo, Y Murakami… - PLoS …, 2012 - journals.plos.org
Non-small-cell lung cancer harboring epidermal growth factor receptor (EGFR) mutations
attains a meaningful response to EGFR-tyrosine kinase inhibitors (TKIs). However, acquired …
attains a meaningful response to EGFR-tyrosine kinase inhibitors (TKIs). However, acquired …
[HTML][HTML] Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor …
W Zhao, A Song, Y Xu, Q Wu, C Liu, JC Yin, Q Ou… - BMC medicine, 2023 - Springer
Background Compound epidermal growth factor receptor (EGFR) mutations are less
responsive to tyrosine kinase inhibitors (TKIs) than single EGFR mutations in non-small cell …
responsive to tyrosine kinase inhibitors (TKIs) than single EGFR mutations in non-small cell …
[HTML][HTML] Long non-coding RNAs in lung cancer: implications for lineage plasticity-mediated TKI resistance
T Liu, C Han, P Fang, H Zhu, S Wang, Z Ma… - Cellular and Molecular …, 2021 - Springer
The efficacy of targeted therapy in non-small-cell lung cancer (NSCLC) has been impeded
by various mechanisms of resistance. Besides the mutations in targeted oncogenes …
by various mechanisms of resistance. Besides the mutations in targeted oncogenes …
[HTML][HTML] Specific Gene Co-variation Acts Better Than Number of Concomitant Altered Genes in Predicting EGFR-TKI Efficacy in Non–small-cell Lung Cancer
Y Zhu, X Qu, D Zhan, H Chen, H Li, L Liu, X Chen… - Clinical Lung Cancer, 2021 - Elsevier
Background There occurs huge heterogeneity in clinical outcomes for epidermal growth
factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) patients treated with …
factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) patients treated with …
Impact of EGFR mutation analysis in non-small cell lung cancer
H Yamamoto, S Toyooka, T Mitsudomi - Lung cancer, 2009 - Elsevier
The discovery of mutations in the tyrosine kinase domain of the epidermal growth factor
receptor (EGFR) gene in non-small cell lung cancer (NSCLC) accelerated the research of …
receptor (EGFR) gene in non-small cell lung cancer (NSCLC) accelerated the research of …